Compare Coinbase Global, Inc. (COIN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Sana Biotechnology Inc — how do they compare? Coinbase Global, Inc. trades at $180.33 (market cap $45.38B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Coinbase Global, Inc. is far larger — about 54.2× Sana Biotechnology Inc's market cap, and Coinbase Global, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Sana Biotechnology Inc for 23 Days on average.
| COIN | SANA | |
|---|---|---|
Market Cap | $45.38B | $836.71M |
Volume | 11,013,940 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $387.00 | $5.92 |
52-Week Low | $141.09 | $2.68 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $43.03B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $179.39, up 0.53% today, with a bullish technical signal despite recent earnings misses. Revenue grew to $7.18B in 2025, but net income margin turned negative at -15.72%. The company maintains strong cash flow from operations at $2.43B and holds $9.55B in cash. Recent CFTC approval for derivatives clearing and expanded Citigroup partnership signal strategic expansion.
Outlook remains mixed with 55% analyst buy ratings and a $211.91 price target, but negative profitability and projected 2026 net loss of -$988M pose significant risks. Stock performance hinges on execution in derivatives and stablecoin initiatives amid volatile crypto markets.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
